BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND LDH
1091 results:

  • 1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
    Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
    Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Advanced melanoma with low-burden and low-risk disease: a clinical case.].
    Bersanelli M
    Recenti Prog Med; 2024 May; 115(5):7e-12e. PubMed ID: 38708540
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines.
    Stouffer M; Wandling E; Dickson L; Lin S; Duan H; Powe E; Jean-Louis D; Tiwari AK; Amos S
    Cancer Rep (Hoboken); 2024 May; 7(5):e2051. PubMed ID: 38702989
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identification of Plasma Lipid Alterations Associated with Melanoma Metastasis.
    Szász I; Koroknai V; Várvölgyi T; Pál L; Szűcs S; Pikó P; Emri G; Janka E; Szabó IL; Ádány R; Balázs M
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673837
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia-reperfusion injury.
    Chen X; Yang T; Zhou Y; Mei Z; Zhang W
    CNS Neurosci Ther; 2024 Apr; 30(4):e14725. PubMed ID: 38615367
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
    Py C; De Vito C; Tsantoulis P; Kaya G; Labidi-Galy SI; Dietrich PY
    Swiss Med Wkly; 2023 Dec; 153():3504. PubMed ID: 38579317
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
    Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
    Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
    Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
    Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Early B cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study.
    Hu W; Wang M; Sun G; Zhang L; Lu H
    Cell Signal; 2024 Jun; 118():111139. PubMed ID: 38479556
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. cellular senescence in testicular cancer. Is there a correlation with the preoperative markers and the extent of the tumor? An experimental study.
    Tatanis V; Veroutis D; Pantelis P; Theocharous G; Sarlanis H; Georgiou A; Peteinaris A; Natsos A; Moulavasilis N; Kavantzas N; Kotsinas A; Adamakis I
    Arch Ital Urol Androl; 2024 Mar; 96(1):12246. PubMed ID: 38441175
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
    Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
    Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: A retrospective analysis.
    Chen Q; Zhao Y; Li P; Duan J; Fu X; Tang Y; Ma Y; Zhou Q
    Skin Res Technol; 2024 Feb; 30(2):e13546. PubMed ID: 38279601
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Real-World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma Patients.
    Rozendorn N; Shutan I; Feinmesser G; Grynberg S; Hodadov H; Alon E; Asher N
    Laryngoscope; 2024 Jun; 134(6):2762-2770. PubMed ID: 38230960
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
    Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Apocynin exerts neuroprotective effects in fumonisin b1-induced neurotoxicity via attenuation of oxidative stress and apoptosis in an animal model.
    Krishnaswamy K; Manasa V; Khan MT; Serva Peddha M
    J Food Sci; 2024 Feb; 89(2):1280-1293. PubMed ID: 38193205
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
    Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
    van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
    Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
    Richtig E; Nguyen VA; Koelblinger P; Wolf I; Kehrer H; Saxinger W; Ressler JM; Weinlich G; Meyersburg D; Hafner C; Jecel-Grill E; Kofler J; Lange-Asschenfeldt B; Weihsengruber F; Rappersberger K; Svastics N; Gasser K; Seeber A; Kratochvill F; Nagler S; Mraz B; Hoeller C
    Melanoma Res; 2024 Apr; 34(2):142-151. PubMed ID: 38092013
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A novel lactate dehydrogenase-based risk score model to predict the prognosis of primary central nervous system germ cell tumor treated with chemoradiotherapy.
    Yao DC; Ye BK; Yao DJ; Guo CC
    Clin Neurol Neurosurg; 2024 Jan; 236():108081. PubMed ID: 38091701
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
    Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
    Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 55.